This article is more than 5 years old. Information may no longer be current.
FDA action tops seven recent developments in psoriasis
The FDA’s approval of Tremfya for treating adults with moderate-to-severe psoriasis who are candidates for systemic therapy or phototherapy was among recent developments reported on Healio.com/Dermatology.
Other developments included study findings that patients with atopic dermatitis had health-related quality of life and productivity impairment that was comparable to patients with psoriasis, and that nail findings distinguished patients with psoriatic arthritis from those with psoriasis without arthritis:
FDA approves Tremfya for psoriasis
Janssen Biotech announced that the FDA has approved Tremfya for treating adults with moderate-to-severe psoriasis who are candidates for systemic therapy or phototherapy.
Tremfya (guselkumab), a human monoclonal antibody, is the only approved biologic therapy that selectively blocks interleukin 23 (IL-23), according to a news release. Read more
Disease burden of atopic dermatitis comparable to psoriasis
Patients with atopic dermatitis had health-related quality of life and productivity impairment that was comparable to patients with psoriasis, according to published study results in the Journal of the American Academy of Dermatology.
Joel M. Gelfand, MD, of the University of Pennsylvania Perelman School of Medicine, and colleagues used data from the U.S. National Health and Wellness Survey to propensity-match patients with atopic dermatitis with control groups of patients without AD and patients with psoriasis. Read more
IL-17, IL-22 expressed differently in pediatric psoriasis patients compared with adults
Pediatric patients with psoriasis showed different patterns of interleukin-17 and interleukin-22 expression than their adult counterparts.
The researchers investigated skin samples from pediatric and adult patients with psoriasis, along with those from healthy controls, to characterize the inflammatory cell profiles of psoriatic plaques. Read more
Nail findings distinguish between psoriasis, psoriatic arthritis
Nail findings distinguished patients with psoriatic arthritis from those with psoriasis without arthritis, with transverse grooves being a significant factor, according to published study results in the Journal of the American Academy of Dermatology.
Researchers conducted a retrospective analysis between July 2003 and February 2015 at the dermatology department of St. Luke’s International Hospital in Tokyo of 118 patients with psoriatic arthritis (PsA; mean age at first visit, 47.7 years; 46.6% female) and 974 patients with psoriasis and without arthritis (mean age at first visit, 50.9 years; 36.2% female). Read more
Cosentyx receives label update for psoriasis treatment in the EU
The interleukin-17 inhibitor Cosentyx (secukinumab, Novartis) received a label update for use in the European Union, according to a press release from the company.
Updated results from a head-to-head trial of Cosentyx (secukinumab, Novartis) and Stelara (ustekinumab, Janssen) demonstrated that secukinumab had long-term superiority in the treatment of moderate-to-severe scalp psoriasis. Read more
Novartis confirms 5-year efficacy for Cosentyx for psoriasis
Novartis has reported positive 5-year efficacy and safety results for Cosentyx from a phase 3 long-term extension study in patients with moderate-to-severe plaque psoriasis.
Data from the study will be presented at a medical congress in the second half of 2017, according to a news release. Read more
Psoriasis registry enrolls 3,000th patient
The National Psoriasis Foundation recently announced that the Corrona Psoriasis Registry, a joint collaboration between the foundation and Corrona, LLC, has enrolled its 3,000th patient.
The Corrona Psoriasis Registry is the largest, independent U.S. registry of psoriasis patients and was launched 2 years ago to compare the safety and effectiveness of FDA-approved psoriasis therapies. Read more